Click on headlines below to download research

Multiple growth drivers lie ahead
Laboratorios Farmacéuticos ROVI | 04/12/2019

Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we…

Moving on from accounting irregularities
Codere | 18/11/2019

Q319 results were dominated by previously announced accounting irregularities in the Mexico, Panama and Colombia divisions. These have been confirmed as…

Robust growth across key franchises
Laboratorios Farmacéuticos ROVI | 08/11/2019

Laboratorios Farmacéuticos ROVI (ROVI) has reported operating revenue of €270.8m (+24% y-o-y) for the first nine months of FY19 (9M19), driven…

Interim Phase II CLEPSIDRA results at ESMO
Oryzon Genomics | 30/09/2019

On 28 September 2019, Oryzon presented additional data from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, at the ESMO congress…

Diversifying outside Argentina
Codere | 19/09/2019

Growth from Mexico and Spain, combined with ongoing operational efficiencies, continues to offset pressure from the Argentine division (23% of Q219 revenues).…

EUR25m debt financing to fund current strategy
ADL Bionatur Solutions | 14/08/2019

ADL Bionatur Solutions (ADL-BS) announced on 12 August 2019 that it has agreed to obtain €25m in debt financing with Kartesia, a private lender, at…

New contract to serve Asia-Pacific API market
ADL Bionatur Solutions | 08/08/2019

ADL Bionatur Solutions (ADL-BS) announced on 7 August 2019 that it entered into a strategic alliance with an undisclosed new customer in Japan to produce…

Outperforming the market
Laboratorios Farmaceuticos ROVI | 01/08/2019

Interim results highlight the momentum at Laboratorios Farmacéuticos ROVI, as both H119 operating revenue (21% y-o-y to €177.5m) and EBITDA…

Amyris contract extended to 2020
ADL Bionatur Solutions | 24/07/2019

ADL Bionatur Solutions (ADL-BS) announced on 22 July 2019 that its existing contract manufacturing (CMO) production agreement with Amyris (AMRS, Nasdaq)…